试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-05-30
Evaluation of the Response of Itraconazole and Terbinafine Therapy in Subjects With Crohn's Disease
编号:NCT05049525登记状态:提前终止企业 / 申办者:Montreal Heart Institute
药物 / 成分:Itraconazole 400 mg/day and terbinafine 500 mg/day administered orally.、Itraconazole's matching placebo 400 mg/day and terbinafine's matching placebo 500 mg/day administered orally.
登记的停止原因(原文):Insufficient patient enrollment
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-05-29
Association Between Fluid Administration, Oxytocin Administration, and Fetal Heart Rate Changes
编号:NCT02121184登记状态:提前终止企业 / 申办者:Northwestern University
药物 / 成分:Routine oxytocin、Half-dose oxytocin
登记的停止原因(原文):The study was terminated due to low enrollment due to competing studies and the PI has now left Northwestern.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-05-29
Fourier Open-label Extension Study in Subjects With Clinically Evident Cardiovascular Disease in Selected European Countries
编号:NCT03080935登记状态:提前终止企业 / 申办者:Amgen
药物 / 成分:Evolocumab
登记的停止原因(原文):Amgen business decision to close study early
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-05-29
Real World Effectiveness of Eptinezumab in Participants With Migraine
编号:NCT05284019登记状态:提前终止企业 / 申办者:H. Lundbeck A/S
药物 / 成分:Eptinezumab、Erenumab、Onabotulinumtoxin-A、Fremanezumab
登记的停止原因(原文):The study was terminated due to enrolment challenges.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-05-29
Erector Spinae Block for Spine Surgery
编号:NCT05417113登记状态:提前终止企业 / 申办者:Icahn School of Medicine at Mount Sinai
药物 / 成分:Liposomal bupivacaine、Bupivacaine
登记的停止原因(原文):recruitment difficulty
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-05-28
Open-label Extension to Protocol 1042-0500
编号:NCT00442104登记状态:提前终止企业 / 申办者:Marinus Pharmaceuticals
药物 / 成分:Ganaxolone
登记的停止原因(原文):Sponsor's decision
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-05-28
Efficacy and Safety of Etonogestrel + 17β-Estradiol Vaginal Ring (MK-8342B) in Women With Primary Dysmenorrhea (With Optional Extension) (MK-8342B-059)
编号:NCT02668783登记状态:提前终止企业 / 申办者:Organon and Co
药物 / 成分:Etonogestrel (ENG) 125 μg + 17β-estradiol (E2) 300 μg vaginal ring、Placebo vaginal ring、Ibuprofen
登记的停止原因(原文):Study terminated by Sponsor as a result of a business decision to discontinue the development program for MK-8342B for reasons unrelated to safety or efficacy.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-05-28
Efficacy and Safety of Etonogestrel + 17β-Estradiol Vaginal Ring (MK-8342B) in the Treatment of Women With Primary Dysmenorrhea (MK-8342B-060)
编号:NCT02668822登记状态:提前终止企业 / 申办者:Organon and Co
药物 / 成分:ENG 125 μg + E2 300 μg vaginal ring (MK-8342B)、Placebo vaginal ring、Ibuprofen
登记的停止原因(原文):Study terminated by Sponsor as a result of a business decision to discontinue the development program for MK-8342B for reasons unrelated to safety or efficacy.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-05-28
Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy
编号:NCT03199040登记状态:提前终止企业 / 申办者:Washington University School of Medicine
药物 / 成分:Durvalumab、Neoantigen DNA vaccine、TDS-IM system (Inchor Medical Systems)、Peripheral blood draw
登记的停止原因(原文):Drugs/equipment unavailable and insufficient funding
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-05-28
Immunotherapy Combined With Radiation and Influenza Vaccine for Pancreatic Cancer.
编号:NCT05116917登记状态:提前终止企业 / 申办者:Herlev Hospital
药物 / 成分:Nivolumab、Ipilimumab、Influenza vaccine、SBRT
登记的停止原因(原文):Based on the precpecified interim analysis the predictive probability was below 10% for the prespecified endpoint.
查看官方原始记录 ↗